Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 116

Similar articles for PubMed (Select 21921273)

1.

Cardiovascular pharmacogenomics.

Roden DM, Johnson JA, Kimmel SE, Krauss RM, Medina MW, Shuldiner A, Wilke RA.

Circ Res. 2011 Sep 16;109(7):807-20. doi: 10.1161/CIRCRESAHA.110.230995. Review.

2.

Cardiovascular drugs and the genetic response.

Dandona S.

Methodist Debakey Cardiovasc J. 2014 Jan-Mar;10(1):13-7. Review.

3.

Cardiovascular pharmacogenomics and individualized drug therapy.

Pereira NL, Weinshilboum RM.

Nat Rev Cardiol. 2009 Oct;6(10):632-8. doi: 10.1038/nrcardio.2009.154. Epub 2009 Aug 25. Review.

4.

Pharmacogenetics and cardiovascular disease--implications for personalized medicine.

Johnson JA, Cavallari LH.

Pharmacol Rev. 2013 May 17;65(3):987-1009. doi: 10.1124/pr.112.007252. Print 2013 Jul. Review.

5.

Pharmacogenetics of heart failure: evidence, opportunities, and challenges for cardiovascular pharmacogenomics.

Wheeler MT, Ho M, Knowles JW, Pavlovic A, Ashley EA.

J Cardiovasc Transl Res. 2008 Mar;1(1):25-36. doi: 10.1007/s12265-007-9007-8. Epub 2008 Jan 29. Review.

PMID:
20559955
6.
7.

Pharmacogenomics: the genetics of variable drug responses.

Roden DM, Wilke RA, Kroemer HK, Stein CM.

Circulation. 2011 Apr 19;123(15):1661-70. doi: 10.1161/CIRCULATIONAHA.109.914820. Review. No abstract available.

8.

Cardiovascular pharmacogenomics: the future of cardiovascular therapeutics?

Roden DM.

Can J Cardiol. 2013 Jan;29(1):58-66. doi: 10.1016/j.cjca.2012.07.845. Epub 2012 Nov 27. Review.

9.

Expanding role of pharmacogenomics in the management of cardiovascular disorders.

Yip VL, Pirmohamed M.

Am J Cardiovasc Drugs. 2013 Jun;13(3):151-62. doi: 10.1007/s40256-013-0024-5. Review.

PMID:
23579966
10.

Pharmacogenetics, pharmacogenomics, and cardiovascular therapeutics: the way forward.

Terra SG, Johnson JA.

Am J Cardiovasc Drugs. 2002;2(5):287-96. Review.

PMID:
14727958
11.

From SNPs to functional studies in cardiovascular pharmacogenomics.

Cresci S.

Methods Mol Biol. 2008;448:379-93. doi: 10.1007/978-1-59745-205-2_12. Review.

PMID:
18370238
12.

The pharmacogenetics of antiplatelet agents: towards personalized therapy?

Ahmad T, Voora D, Becker RC.

Nat Rev Cardiol. 2011 Aug 9;8(10):560-71. doi: 10.1038/nrcardio.2011.111. Review.

PMID:
21826075
13.

Pharmacogenetics of chronic cardiovascular drugs: applications and implications.

Zineh I, Johnson JA.

Expert Opin Pharmacother. 2006 Aug;7(11):1417-27. Review.

PMID:
16859425
14.

Therapeutic relevance of pharmacogenetic factors in cardiovascular medicine.

Nakagawa K, Ishizaki T.

Pharmacol Ther. 2000 Apr;86(1):1-28. Review.

PMID:
10760544
15.

Cardiovascular pharmacogenetics.

Myburgh R, Hochfeld WE, Dodgen TM, Ker J, Pepper MS.

Pharmacol Ther. 2012 Mar;133(3):280-90. doi: 10.1016/j.pharmthera.2011.11.002. Epub 2011 Nov 22. Review.

PMID:
22123178
16.

Prospects of personalized medicine in cardiovascular diseases.

Lenfant C.

Metabolism. 2013 Jan;62 Suppl 1:S6-10. doi: 10.1016/j.metabol.2012.08.018. Epub 2012 Sep 21.

PMID:
22999711
18.

Cardiovascular agents.

Walton T, Thomas R.

Semin Dial. 2010 Sep-Oct;23(5):480-2. Review. No abstract available.

PMID:
21069921
19.

Pharmacogenomics, pharmacokinetics and pharmacodynamics: interaction with biological differences between men and women.

Franconi F, Campesi I.

Br J Pharmacol. 2014 Feb;171(3):580-94. doi: 10.1111/bph.12362. Review.

20.

Applied pharmacogenomics in cardiovascular medicine.

Weeke P, Roden DM.

Annu Rev Med. 2014;65:81-94. doi: 10.1146/annurev-med-101712-122545. Epub 2013 Oct 2. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk